



BodeVet Awarded \$1.7 Million U.S. Army Contract to Conduct Veterinary Clinical Trial in Polytrauma Canine Patients

Study will evaluate administration and effects of freeze-dried platelets and plasma

ROCKVILLE, Md. (June 3, 2020) – BodeVet, Inc., a Maryland-based company focused on the development of novel blood products for use in veterinary transfusion, announced today that the U.S. Army Medical Research Acquisition Activity (USAMRAA) has awarded the company a 2-year contract valued at \$1.7 million to conduct a clinical trial in canine polytrauma patients at veterinary critical care hospitals. The study is designed to evaluate the administration of two lyophilized blood products, StablePlate RX® Canine (lyophilized canine platelets) and StablePlas™ Canine (lyophilized canine plasma) and their effects on hemodynamic stabilization following trauma, and to determine survival benefit when compared to current veterinary standard of care for trauma resuscitation.

“We are pleased that USAMRAA has awarded BodeVet with this contract to conduct this unique veterinary clinical trial that could help advance hemorrhage control protocols, benefiting military working dogs, veterinary clinical patients, and, ultimately, human military and civilian trauma patients,” said Anne Hale, DVM, Chief Technology Officer of BodeVet. “Hemorrhagic shock is a major cause of death in veterinary patients, particularly in cases of trauma. Data from a recent study has shown that canine freeze-dried platelets significantly reduce bleeding in dogs and could be lifesaving for the treatment of trauma. We believe the combination of freeze-dried platelets and freeze-dried plasma could advance canine trauma resuscitation efforts to human trauma standards.”

Based on mortality data from military and civilian studies, revised resuscitation guidelines emphasize use of platelets and plasma with minimized crystalloid resuscitation to significantly increase rates of survival following trauma. However, many veterinary clinics and emergency care centers have a limited supply of canine blood products for immediate transfusion to stabilize emergent critical patients. Treatment of injured military, search and rescue, and police working canines further highlight these resource constraints for stabilization of these patients. Freeze-dried platelets and plasma, like StablePlate RX and StablePlas, can be stored at ambient temperatures for years and can be readily available at all levels of care, filling a void in the care of military operational canine units and civilian veterinary clinics.

The clinical trial will be conducted with the participation and support of members of The American College of Veterinary Emergency and Critical Care’s Veterinary Committee on Trauma.

BodeVet’s StablePlate RX Canine, which is sold commercially, is targeted to treat life-threatening hemorrhage secondary to thrombocytopenia and trauma. The product is available as dry powder in a vial, ready for reconstitution with sterile water and infusion at the point of care. StablePlas Canine is in development.

(MORE)

BodeVet and its parent company, Cellphire Inc., the global leader in long-term stabilization and storage of platelets, hope the data from this study will advance research and development of human hemostatic therapies such as Cellphire's platelet-based freeze-dried hemostatic, Thrombosomes®. The companies have adopted the U.S. Food and Drug Administration's OneHealth Initiative, which aims to promote, improve, and defend the health of all species through the integration of human and veterinary medicine. Cellphire and BodeVet are leveraging clinical animal data to seek approval for veterinary products and to provide the translational data needed to support human clinical trials.

###

About BodeVet

BodeVet, a wholly owned subsidiary of Cellphire, Inc., is solving the unmet needs of companion and exotic animals for transfusion medicine and regenerative therapies. The company launched its first commercial product, StablePlateRX® Canine, a freeze-dried hemostatic agent derived from canine platelets in 2017. Built on a socially responsible sourcing, cGMP manufacturing, and product consistency, BodeVet helps the veterinary community provide more predictable and favorable outcomes. To learn more, visit www.bodevet.com.

This work is supported by the U.S. Army Medical Research and Development Command under Contract No. W81XWH20C0067.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

In conducting research using animals, the investigator(s) will adhere to the Animal Welfare Act Regulations and other Federal statutes relating to animals and experiments involving animals and the principles set forth in the current version of the Guide for Care and Use of Laboratory Animals, National Research Council.